Introduction {#Sec1}
============

Due to advances in medical technology, outcomes for preterm infants treated in neonatal intensive care units (NICUs) have improved during the latest 20 years \[[@CR1]\]. However, more than 40% of very preterm infants still die before discharge or suffer from one or more serious complications \[[@CR2]\] that can lead to further poor neurodevelopmental outcomes \[[@CR3]\]. Most preterm infant deaths, especially those born\<28 weeks gestation, were caused by infections, including sepsis and necrotizing enterocolitis (NEC). These morbidities are associated with increased mortality, morbidity, and prolonged lengths of hospital stay \[[@CR3], [@CR4]\].

The gut microbial composition of preterm infants is quite different from that of full-term infants. Preterm infants have low bacterial diversity and a different gut microbiota, with more Proteobacteria and *Enterococcus*, which are regarded as potential pathogenic bacteria in their intestinal tract \[[@CR5]\]. In addition, the digestive system of preterm infants is immature, with an underdeveloped intestinal mucosa barrier \[[@CR6]\]. Pathogens and bacterial toxins can pass through their gut barrier easily and enter blood and lymph circulation, leading to life-threatening infections, including sepsis, NEC, and diarrhea. There are many factors that may lead to intestinal dysbacteriosis of preterm infants, such as lack of fresh breast milk, delayed introduction of enteral feeding, and excessive antibiotic use in the NICU \[[@CR6], [@CR7]\]. After birth, most preterm infants stay in the hospital to receive observation and treatment for at least 1--2 weeks, which can expose them to a higher incidence of opportunistic infections \[[@CR8]\].

In recent years, much attention has been given to providing preterm infants with prebiotics supplements to promote growth and development and prevention of various morbidities. Prebiotics supplementation in preterm infants may facilitate the growth and proliferation of probiotic bacteria in their intestinal tract and has been found to prevent the overgrowth of pathogens and promote the maturation of the intestinal mucosa. However, due to their immature immune and digestive systems \[[@CR9]\], prebiotic supplementation dosage levels should be considered carefully to avoid feeding intolerance.

Non-human milk oligosaccharides, which have been manufactured to function in a similar manner to oligosaccharides in breast milk \[[@CR7]\], include neutral short-chain galacto-oligosaccharides (scGOS), long-chain fructo-oligosaccharides (lcFOS), and pectin-derived acidic oligosaccharides (pAOS). In addition to neutral oligosaccharides (scGOS/lcFOS), few clinical trials are concerned with acidic oligosaccharides (pAOS), which could directly modify the immune system of infants \[[@CR7]\].

Many meta-analyses focused on evaluating if probiotics have shown beneficial effects in preterm infants, but few have focused on the effect of prebiotics. Furthermore, there are no meta-analyses that evaluate the effect of pAOS in relation to preterm infants. We aimed to perform a meta-analysis of studies published over the past 18 years, in which randomized control trials (RCTs) were used to evaluate whether prebiotics could confer a health benefit to preterm infants, especially in reducing the incidence of sepsis, NEC, and mortality. Furthermore, this study also considered other important outcomes in preterm infants, including prolonged length of hospital stay, feeding intolerance, and stool frequency.

Methods {#Sec2}
=======

Search strategy {#Sec3}
---------------

The study protocol was registered in the PROSPERO database (registration ID: CRD42017068320). The PICO approach was used to assist in identifying relevant studies as follows: P (population): study population comprising preterm or low birth weight infants, and all trials involved human participants; I (intervention): use one of the following supplements as intervention: scGOS, lcFOS, pAOS, oligosaccharides, fructans, inulin, or oligofructose as intervention; C (comparison): placebo-controlled trials involved participants randomized allocation to treatment groups; O (outcome): report one or more of the following outcomes: morbidity rate of sepsis, NEC, mortality, feeding intolerance, time to achieve full enteral feeding, stool frequency, and length of hospital stay. If the authors published multiple articles from the same population, we only chose those with the largest sample sizes and the longest intervention duration.

The following items were combined and used to conduct a systematic search to identify suitable trials: prebiotics AND preterm infant or low weight birth infant AND search filters for RCTs. When relevant data was not adequately provided in articles, we contacted the authors by e-mail in an attempt to retrieve the missing information needed for the meta-analysis.

Inclusion criteria {#Sec4}
------------------

We used the following criteria to determine the inclusion of RCTs: (1) Published in a peer-reviewed journal in the past 18 years (January 2000 until June 2018); (2) Study design was a RCT; (3) Participants included low birth weight infants (\<2500 g) or preterm infants (\<36 weeks); (4) Prebiotics and placebo were supplied to different groups as an intervention; and (5) Outcome variables included incidence of sepsis, NEC, mortality, time to achieve full enteral feeding, feeding intolerance, stool frequency, and length of hospital stay.

Data extraction and quality assessment {#Sec5}
--------------------------------------

Two researchers independently extracted data and conducted an assessment of trials according to the criteria above. Relevant studies from January 2000 to June 2018 were searched and selected from PubMed, Medline, Scopus, and the Cochrane Library. A summary of the review was presented using the PRISMA flow chart (Fig. [1](#Fig1){ref-type="fig"}). We extracted the following data from each of the included articles: study location, population, study design, type of prebiotics, and placebo used as the intervention, details of the main study endpoints, blinding, form and dosage of prebiotics used, duration, information to assess the risk of bias, and major outcomes reported. We used the Physiotherapy Evidence Database (PEDro) tool to evaluate the quality of the included literature. Studies were then categorized into three levels using the tool (high, 8 or more points; moderate, 4--7 points; low, 3 points or less). Studies that were categorized as moderate or high quality were included in the analysis, while poor studies were excluded.Fig. 1The preferred reporting items for systematic reviews and meta-analyses flow chart representing the reviewing process

Statistical analysis {#Sec6}
--------------------

A pooled effect size method was used to describe the effect of prebiotics on health outcome variables. We used random effect models to assess the between-study variation. Risk ratios were calculated to examine the effect size for sepsis, NEC, mortality, and feeding intolerance. Mean difference was used to present the effect of time to achieve full enteral feeding, stool frequency as well as length of hospital stay. The pooled mean difference with a 95% Confidence Interval (CI) was figured up to assess the effects of prebiotics on the infants' health outcomes. Several methods were used to estimate heterogeneity among the pooled studies, including *I*^2^ statistics as well as visual inspection of CI overlap. Low heterogeneity was defined as trials with *I*^2^ \< 50%. We performed a subgroup analysis to identify the sources of heterogeneity associated with the effects of birth weight (\<1500 g compared with 1500--2500 g), duration of intervention (\<28 days compared with 28 days or more), quality of RCTs (high compared with moderate), the forms of prebiotics used (milk compared with other forms), dosage of prebiotics (\<1.5 g/kg/day vs. 1.5 g/kg/day), and type of prebiotics (pAOS compared with no pAOS). The Egger test was used to assess any publication bias together with a visual inspection of funnel plots. Sensitivity analyses were performed to assess whether the efficacy of prebiotics was derived from one particular trial or multiple trials.

Results {#Sec7}
=======

In the initial systematic search, 105 articles were identified from the databases listed above (Fig. [1](#Fig1){ref-type="fig"}). After duplications were removed, 47 articles were listed. After reading titles and abstracts, 30 potentially relevant articles were identified. Full articles were retrieved and reviewed, then another 12 studies were excluded (six due to insufficient data, four due to not focusing on preterm infants, two due to being non-human population RCT's). The final statistical analysis was conducted with the remaining 18 articles, which consisted of 12 high quality (8 points or more) and six moderate quality (4--7 points) articles.

The 18 RCTs reported health outcomes on 647 infants given prebiotics and 675 infants as control. Samples were drawn from ten different locations, including Iran \[[@CR10]--[@CR12]\], Netherlands \[[@CR13]--[@CR18]\], Turkey \[[@CR19]\], Greece \[[@CR20], [@CR21]\], Finland \[[@CR22]\], France \[[@CR23]\], Israel \[[@CR24]\], England \[[@CR25]\], Germany \[[@CR26]\], and Italy \[[@CR27]\]. Among the 18 trials, 11 were double-blinded \[[@CR11], [@CR12], [@CR14], [@CR15], [@CR19], [@CR21]--[@CR26]\], and the rest seven were single blinded \[[@CR10], [@CR16]--[@CR18], [@CR20], [@CR27]\]. All studies included one or more of the following outcomes: incidence of sepsis, NEC, death, time to full achieve enteral feeding, feeding intolerance, stool frequency, and length of time in hospital. The characteristics of included trials and quality assessment results are presented in Table [1](#Tab1){ref-type="table"}.Table 1Characteristics of 18 included randomized controlled trialsStudiesParticipants at beginning, *n* (P/C)Design, locationGestational age, P/C, weekBirth weight, P/C, gSex, *n* (P/C, M/F)Treatment duration, daysPrebiotics usedDosePlaceboMeasured outcomesKey outcomesQuality of studies assessed by PEDro toolFormArmanian et al. \[[@CR11]\]50 (25/25)DB, Iran30.48 (2.31)/29.80 (2.16)1.262 (0.213)/1.188 (0.194)Not mentioned21scGOS/lcFOS1.5 g/kg/dayDistilled waterFecal microbiota pattern, duration of dependency to oxygen, hospitalization, and deathLed to the rapid growth of beneficial Lactobacillus colonies11Mixture solutionVan den Berg et al. \[[@CR18]\]77 (38/39)SB, Netherlands29.9 (1.7)/29.6 (2.1)1.32 (0.38)/1.28 (0.28)21/17, 24/1528scGOS/lcFOS/pAOS1.5 g/kg/dayBreast milk or formulaNeurodevelopment, cytokines, and infectionsNo significant improvement of neurodevelopmental outcomes8With breast milk or formulaArmanian et al. \[[@CR12]\]50 (25/25)DB, Iran30.4 (2.3)/29.8 (2.1)1.262 (0.213)/1.188 (0.194)Not mentioned7scGOS/lcFOS1.5 g/kg/dayDistilled waterBilirubin level and stool frequencyIncrease stool frequency, improve feeding tolerance, and reduce bilirubin level11Mixture solutionDilli et al. \[[@CR19]\]200 (50/50)DB, Turkey29.0 (1.7)/28.2 (2.2)1.229 (0.246)/1.147 (0.271)52/48, 58/4256Inulin1.35 g/kg/dayMaltodextrinNEC, sepsis, mortality, duration of hospitalInulin could not decrease NEC10With breast milk or formulaArmanian et al. \[[@CR10]\]75 (25/50)SB, Iran30.48 (2.31)/30.38 (2.53)1.263 (0.213)/1.206 (0.177)Not mentioned14scGOS/lcFOS1.5 g/kg/dayDistilled waterNEC, mortality, sepsis, feeding intolerance, and days to reach full enteral feedingLower NEC, mortality, sepsis rates, and shorter days to reach full enteral feeding8With breast milk or formulaDasopoulou et al. \[[@CR21]\]167 (85/82)DB, Greece34.0 (0.33)/34.0 (0.33)2.019 (0.30)/1.987 (0.38)Not mentioned16scGOS/lcFOS1.2 g/kg/dayFormulaMotilin, NEC, mortality, sepsis, and feeding intoleranceIncrease motilin, reduce gastric residue11With formulaLuoto et al. \[[@CR22]\]47 (23/24)DB, Finland32--352.123 (0.39)/2.412 (0.84)11/12, 19/557scGOS/polydextrose1.2 g/kg/dayMicrocrystalline cellulose and dextrose anhydrateRespiratory tract infections and its durationReduce the risk of rhinovirus infections11With breast milk or formulaVan den Berg et al. \[[@CR16]\]103 (55/58)SB, Netherlands29.9 (1.9)/29.3 (2.1)1.3 (0.4)/1.2 (0.3)31/24, 36/2228scGOS/lcFOS/pAOS1.5 g/kg/dayMaltodextrinSerious infectious morbidityDoes not improve the immunization response10With breast milk or formulaLeCouffe et al. \[[@CR17]\]113 (48/45)SB, Netherlands30.2 (1.6)/29.5 (2.0)1.37 (0.4)/1.26 (0.3)26/48, 26/4528scGOS/lcFOS/pAOS1.5 g/kg/dayMaltodextrinNeurodevelopmental outcomeNo effect on neurodevelopmental8With breast milk or formulaNiele et al. \[[@CR15]\]114 (48/46)DB, Netherlands30.1 (1.6)/29.5 (2.0)1.40 (0.4)/1.30 (0.3)Not mentioned28scGOS/lcFOS/pAOS1.5 g/kg/dayMaltodextrinAllergic and infectious diseasesDoes not decrease the incidence of allergic and infectious diseases10With breast milk or formulaWesterbeek et al. \[[@CR14]\]103 (55/58)DB, Netherlands29.9 (1.9)/29.3 (2.1)1.3 (0.4)/1.2 (0.3)31/24, 36/2228scGOS/lcFOS/pAOS1.5 g/kg/dayMaltodextrinStool viscosity, stool frequency, and stool pHDecreases stool viscosity and stool pH, increased stool frequency11With breast milk or formulaCampeotto et al. \[[@CR23]\]58 (24/34)DB, France33.5 (1.3)/33.4 (1.1)1.91 (0.35)/1.93 (0.39)15/9, 16/1830Fermente induced non-digestible oligosaccharidesNot mentionedFormulaInflammatory and immune markersBenefits on inflammatory and immune markers10FormulaRiskin et al. \[[@CR24]\]28 (15/13)DB, Israel30.3 (2.8)/28.7 (2.9)1.52 (0.55)/1.21 (0.45)10/5, 5/835Lactulose1.5 g/kg/dayDextroseNEC, mortality, sepsis, feeding intolerance, and days to reach full enteral feedingSuggest positive prebiotic effects10Mixture solutionModi et al. \[[@CR25]\]154 (73/81)DB, UK30.0 (0.5)/31.0 (0.5)1.57 (0.88)/1.52 (0.91)48/25, 50/3128scGOS/lcFOS1.2 g/kg/dayFormulaNEC, mortality, sepsis, feeding intoleranceSafe and may benefit enteral tolerance11FormulaKapiki et al. \[[@CR20]\]56 (36/20)SB, Greece33.4 (1.8)/33.9 (1.3)1.59 (0.33)/1.64 (0.17)16/17, 8/127scGOS0.6 g/kg/dayMaltodextrinBifidogenic effect, stool characteristicsSmall quantity of prebiotic is well accepted7FormulaMihatsch et al. \[[@CR26]\]20 (10/10)DB, Germany27.1 (2.2)/27.6 (3.3)0.89 (0.64)/0.90 (0.69)Not mentioned14scGOS/lcFOS1.5 g/kg/dayMaltodextrinStool characteristicsReduce stool viscosity11FormulaBoehm et al. \[[@CR27]\]27 (12/15)SB, Italy31.2 (0.6)/31.4 (0.9)1.59 (0.24)/1.60 (0.32)8/7, 7/528scGOS/lcFOS1.5 g/kg/dayMaltodextrinStool characteristicsMore frequent and softer stools8FormulaValues are means (SDs) unless otherwise indicated*scGOS/lcFOS* short chain galacto-oligosaccharides/long chain fructo-oligosaccharides, *pAOS* pectin-derived acidic oligosaccharides, *DB* double blind, *SB* single blind, *P/C* prebiotic group/control group

Effects on sepsis {#Sec8}
-----------------

Eleven trials, with 1106 infants, reported sepsis rates. The mean morbidity rate for the infants receiving prebiotics was 17.4% compared with 27.4% in the controls. The results of meta-analysis showed a significant decrease in risk ratio of 0.64 (95% CI: 0.51, 0.78; *P* \< 0.001) in the group of preterm infants receiving prebiotic treatment compared with that of the control group, with no significant heterogeneity among studies (*I*^2^ = 0%, *P* = 0.66) (Fig. [2a](#Fig2){ref-type="fig"}).Fig. 2Forest plots of the effects of prebiotics on sepsis (**a**), necrotizing enterocolitis (**b**), mortality (**c**), and feeding intolerance (**d**)

Subgroup analysis (Table [2](#Tab2){ref-type="table"}) showed that prebiotics supplementation could significantly reduce the incidence of sepsis when treatment duration was ≥28 days (*P* \< 0.01) compared with \<28 days (*P* = 0.15). It is notable that trials that supplied prebiotics using breast milk plus preterm formula milk (*P* \< 0.001) as the medium achieved better results in lowering sepsis risk compared with trials using distilled water (*P* = 0.28). It was also found that the effect of prebiotics on reducing sepsis was statistically significant when the quality assessed to be high (*P* \< 0.001) compared with moderate quality ones (*P* = 0.17). A significant beneficial effect was also demonstrated in studies using prebiotics with pAOS (*P* \< 0.001) compared with prebiotics without pAOS (*P* = 0.13).Table 2Subgroup analysis on the effects of probiotics on sepsis, necrotizing enterocolitis, and mortalitySubgroupsSepsisNecrotizing enterocolitisMortalityStudies, *n*Participants, *nI*^2^Risk ratio95% CI*P*Studies, *n*Participants, *nI*^2^Risk ratio95% CI*P*Studies, *n*Participants, *nI*^2^Risk ratio95% CI*P*Birth weight0.660.920.54 \<1500 g66524%0.650.51, 0.84\*\*\*338861%0.770.29, 2.0637420%0.560.34, 0.91\* 1500- 2500 g54540%0.590.39, 0.88\*\*33490%0.710.25, 2.0731823%1.040.15, 7.15Duration of intervention0.760.180.17 \<28 days22420%0.640.51, 0.80\*\*\*22420%0.390.13, 1.2421250%2.380.30, 18.75 ≥28 days98640%0.630.51, 0.78\*\*\*449517%0.970.51, 1.8347710%0.540.33, 0.90\*Form of prebiotics0.620.60.68 Milk1010780%0.640.52, 0.79\*\*\*570934%0.820.42, 1.6258460%0.570.35, 0.93\* Other128Not applicable0.430.09, 1.99128Not applicable0.430.04, 4.251786%0.920.09 9.07Quality of study0.10.130.83 High88610%0.550.42, 0.72\*\*\*56620%0.880.54, 1.4356588%0.560.29, 1.07 Moderate32450%0.790.57, 1.11175Not applicable0.180.02, 1.3312660%0.620.29, 1.35Dosage0.20.920.87 \<1.5 g/kg/day45680%0.550.41, 0.75\*\*\*35210%0.70.39, 1.26335470%0.510.04, 6.34 1.5 g/kg/day64800%0.730.54, 0.98\*321660%0.640.14, 3.0235700%0.640.38, 1.07Type of prebiotics0.090.060.83 Without pAOS43770%0.780.57, 1.0756240%0.670.36, 1.06550734%0.70.18, 2.65 With pAOS77290%0.540.41, 0.72\*\*\*1113Not applicable1.760.68, 4.5114170%0.590.34, 1.02\**P* \< 0.05, \*\**P* \< 0.01, \*\*\**P* \< 0.001

Effects on NEC {#Sec9}
--------------

Six trials, with 737 infant included, presented the morbidity rate of NEC. The mean NEC rate in the prebiotics intervention and control group was 8.2% and 11.2%, respectively. The meta-analysis showed a non-significant risk ratio of 0.79 (95% CI: 0.44, 1.44; *P* = 0.44) between the two groups administered prebiotics and placebo. The heterogeneity of trials was not significant (*I*^2^ = 21%, *P* = 0.27) (Fig. [2b](#Fig2){ref-type="fig"}). No significant difference was found between the two groups in morbidity rate of NEC, considering birth weight, treatment duration, form of prebiotics, quality of studies, dosage, and the administration of pAOS (Table [2](#Tab2){ref-type="table"}).

Effects on mortality {#Sec10}
--------------------

Nine trials, including 924 participants, reported the mortality rates of preterm infants. The mean death rate in the infants receiving prebiotics was 5.4% vs. 9.7% in the controls. The meta-analysis showed a significantly lower risk ratio of 0.58 (95% CI: 0.36, 0.94; *P* \< 0.001) in the prebiotics intervention infants compared with the infants receiving the placebo. The heterogeneity of trials was not significant (*I*^2^ = 0%, *P* = 0.62) (Fig. [2c](#Fig2){ref-type="fig"}).

Subgroup analysis (Table [2](#Tab2){ref-type="table"}) showed that the prebiotics supplementation could significantly reduce the morbidity rate of sepsis when treatment duration was 28 days or more (*P* \< 0.05) compared with infants receiving prebiotics less than 28 days (*P* = 0.41). The trials administering prebiotics, along with a combination of breast milk and preterm formula (*P* \< 0.05), had a greater effect on mortality compared with trials that used distilled water (*P* = 0.95). The results also showed that prebiotics treatment had a greater effect on reducing the death rate in trials with high quality (*P* \< 0.001) compared with that of moderate quality (*P* = 0.17). In addition, prebiotics treatment had a significant effect on preterm infants with a birth weight less than 1500 g (*P* \< 0.05) but not with preterm infants with a birth weight ≥1500 g (*P* = 0.97).

Effects on feeding intolerance {#Sec11}
------------------------------

Four trials, involving 413 infants, reported the incidence of infant feeding intolerance. The mean feeding intolerance rate in infants administered prebiotics was 7.4% compared with 13.4% in controls. There was a non-significant risk ratio of 0.87 (95% CI: 0.52, 1.45; *P* = 0.60) between the infants receiving the prebiotics intervention compared to the placebo. The heterogeneity of trials was not significant (*I*^2^ = 0%, *P* = 0.34) (Fig. [2d](#Fig2){ref-type="fig"}). No significant difference in reducing the incidence of feeding intolerance was found by subgroup analysis, considering birth weight, treatment duration, form of prebiotics, quality of studies, dosage, and the administration of pAOS.

Effects on time to achieve full enteral feeding {#Sec12}
-----------------------------------------------

Six studies, including 576 infant participants, measured time to achieve full enteral feeding. The results of meta-analysis showed a significantly shorter time to achieve full enteral feeding in the prebiotic group when compared with the control group (MD −0.99, 95% CI: −1.15, 0.83, *P* \< 0.001). The heterogeneity of included trials was not significant (*I*^2^ = 0%, *P* = 0.85) (Fig. [3a](#Fig3){ref-type="fig"}). Subgroup analysis (Table [3](#Tab3){ref-type="table"}) indicated that trials that administered prebiotics along with a combination of human breast milk and preterm formula (*P* \< 0.05) tended to be more effective compared with the trial using distilled water (*P* = 1). The results also showed that the effect of prebiotics on reducing time to full enteral feeding was statistically significant in trials of high quality (*P* \< 0.001) compared to trials of moderate quality (*P* = 0.39). One study \[[@CR10]\] with a 14-day intervention showed no significant difference between groups using prebiotics or not (*P* = 0.22). Five studies \[[@CR14], [@CR16], [@CR17], [@CR24], [@CR25]\] showed that the infant receiving prebiotics spent less time in achieving full enteral feeding compared to the controls (*P* \< 0.01).Fig. 3Forest plots of the effects of prebiotics on time to full enteral feeding (**a**), length of hospital stay (**b**), and stool frequency (**c**)Table 3Subgroup analysis on the effects of probiotics on time to full enteral feeding, length of hospital stay, and stool frequencySubgroupsTime to full enteral feedingLength of hospital stayStool frequencyStudies, *n*Participants, *nI*^2^Mean difference95% CI*P*Studies, *n*Participants, *nI*^2^Mean difference95% CI*P*Studies, *n*Participants, *nI*^2^Mean difference95% CI*P*Birth weight0.640.390.04 \<1500 g559494%−1.8−5.21, 1.61665880%−6.6−10.03, −3.08\*\*\*31830%0.340.10, 0.58\*\*\* 1500--2500 g21820%−1−1.16, −0.8427517%−1.07−13.05, 10.9131110%0.740.44, 1.05\*\*\*Duration of intervention0.990.550.55 \<28 days175Not applicable−1.5−3.88, 0.88217573%−6.95−11.51, −1.68\*\*\*31260%0.630.32, 0.95\*\*\* ≥28 days670198%−1.47−4.29, 1.36655885%−3.87−11.38, 3.64316840%0.480.11, 0.86Form of prebiotics0.490.120.48 Milk674898%−1.67−4.43, 1.08665588%−3.4−9.71, 2.91421646%0.60.27, 0.93\*\*\* Other128Not applicable0−3.88, 3.882780%−8.65−10.35, −6.94\*\*\*2780%0.4−0.05, 0.85\*\*\*Quality of study0.580.130.03 High560899%−1.76−4.92, 1.4543886%−6.98−11.31, −2.65\*\*\*42110%0.340.11, 0.58\*\*\* Moderate21680%−0.74−2.4, 0.9332950%−2.44−6.41, 1.522830%0.790.47, 1.12\*\*\*Dosage0.240.890.16 \<1.5 g/kg/day2354100%−3.49−8.39, 1.41224795%−5.75−18.48, 6.98156Not applicable0.750.34, 1.16\*\*\* 1.5 g/kg/day54220%−0.46−1.65, 0.73648649%−4.8−8.78, −0.82\*52380%0.420.21, 0.64\*\*\*Type of prebiotics0.270.030.06 Without pAOS445799%−2.29−5.8, 1.23538992%−10.81−19.62, −2.01\*51810%0.660.41, 0.92\*\*\* With pAOS33190%−0.13−1.6, 1.3332830%−7.16−6.63, 4.951113Not applicable0.30.02, 0.58\*\**P* \< 0.05, \*\**P* \< 0.01, \*\*\**P* \< 0.001

Effects on length of hospital stay {#Sec13}
----------------------------------

Eight trials, comprising 733 infant participants, reported the length of hospital stay. Data from six studies \[[@CR10], [@CR12], [@CR14], [@CR18], [@CR19], [@CR24]\] showed that the infants received prebiotic supplement had a shorter length of hospital stay, while two studies \[[@CR17], [@CR22]\] did not observe any significant difference on this variable. The meta-analysis showed a significant reduction in length of hospital stay of 0.58 (MD −5.18, 95% CI: −8.94, −1.11, *P* = 0.007) (Fig. [3b](#Fig3){ref-type="fig"}) in the prebiotics intervention infants compared with the infants receiving the placebo. The heterogeneity of trials was significant (*I*^2^ = 83%, *P* \< 0.001), and subgroup analysis (Table [3](#Tab3){ref-type="table"}) did not improve the heterogeneity. We also performed a sensitivity analysis to address the heterogeneity and confirm the stability of our results. The cumulative sensitivity test also demonstrated the total effect was not due to any single study.

Effects on stool frequency {#Sec14}
--------------------------

Six studies with 294 infant participants measured stool frequency. The stool frequency in the prebiotic group was significantly higher when compared to the control group (MD 0.52, 95% CI: 0.3, 0.73, *P* \< 0.001). The heterogeneity of trials was not significant (*I*^2^ = 13%, *P* = 0.33) (Fig. [3c](#Fig3){ref-type="fig"}). Studies with prebiotics administered via a combination of breast and formula milk (*P* \< 0.001) showed a significantly higher stool frequency compared with studies that used other mediums (*P* = 0.08). In addition, subgroup analysis showed no significant difference in stool frequency, considering birth weight, treatment duration, quality of studies, and dosage (Table [3](#Tab3){ref-type="table"}).

Publication bias {#Sec15}
----------------

The visual inspection of each funnel plots showed no obvious publication bias associated with the efficacy of prebiotics on infection, feeding intolerance, time to full enteral feeding, mortality, NEC, stool frequency, and length of stay in hospital. This conclusion was supported by results from the Egger's test (sepsis: *P* = 0.80, NEC: *P* = 0.73, mortality: *P* = 0.73, time to full enteral feeding: *P* = 0.63, length of hospital stay: *P* = 0.08, stool frequency: *P* = 0.32) (Table [4](#Tab4){ref-type="table"}), which showed no statistically significant evidence of publication bias.Table 4Publication bias illustrated by Egger testVariable name*t* (95% CI)*P*Sepsis0.26 (−2.42, 1.93)0.8NEC0.36 (−3.90, 3.99)0.73Mortality0.36 (−3.90, 3.99)0.73Time to full enteral feeding0.52 (−11.27, 7.49)0.63Length of hospital stay2.11 (−0.33, 4.51)0.08Stool frequency1.13 (−2.18, 5.16)0.32

Discussion {#Sec16}
==========

Overall, the results, based on our meta-analysis, showed that prebiotics can improve the health of preterm infants, including decreasing the incidence of sepsis and death, reducing time to achieve full enteral feeding and hospital stay, increasing the stool frequency. Besides, the effects of prebiotics on the risk of feeding intolerance and NEC were not statistically significant. Despite improvements in NICU healthcare provided by experienced neonatologists, the morbidity rate of sepsis and NEC remain high in preterm infants \[[@CR28]\]. This is concerning because a reduction in the morbidity rate of sepsis and NEC can significantly reduce the complications and death rate associated with premature delivery.

Our results showed prebiotics supplementation could reduce the risk of NEC, which is consistent with previous published studies \[[@CR29], [@CR30]\]. However, unlike our study, previous reviews included less trials and had smaller sample sizes which reduced the power to assess for clinically important main outcomes. Our study included more RCT trials focused on medical complications and key variables. We also conducted subgroup analyses to reveal the effect of prebiotics with or without pAOS, and therefore, the effect of pAOS on reducing sepsis could be indicated.

The mechanism of prebiotics in decreasing the risk of sepsis and mortality might be related to preventing colonization of pathogenic bacteria and the overgrowth of opportunistic pathogens \[[@CR31]\]. In addition, prebiotics can improve intestinal motility and intestinal permeability of preterm infants, leading to a better intestinal integrity of the epithelial surface. The combine action between the restrain of pathogens and inhibition of pathogens adhere to the epithelial surface may also be involved in promoting the resistance of preterm infants to endogenous infections \[[@CR32], [@CR33]\].

Subgroup analyses showed the beneficial effects of prebiotics on lowering the morbidity rate of sepsis and death might be due to the effects of preterm infants' gestational age, prebiotic forms, and prebiotic types (added pAOS). Potential mechanisms by which prebiotics protect preterm infants from high risk of sepsis may relate to increasing the barrier to prevent the pathogenic bacteria and toxins from migrating across the intestinal mucosa, promoting a competitive exclusion of potential pathogens. Furthermore, prebiotics could modify hosts' response to bacterial toxins and enhance their immune responses.

In our study, we found newborns with a gestational age \<28 weeks would benefit less from prebiotic supplementation. The immune system, intestinal mucosa barrier as well as a distinct gut microbiota of these very low birth weight infants are less developed \[[@CR5]\]. Due to excessive antibiotic use in these high-risk infants, antibiotic treatment before and after birth may have dramatically affected the composition of their gut microbiota, and caused intestinal dysbacteriosis \[[@CR34]--[@CR36]\]. The imbalance needs to be addressed through the use of probiotics \[[@CR37]\] or synbiotics \[[@CR38]--[@CR40]\]. Using prebiotics alone may do little to re-establish micro-ecological balance after excessive antibiotic exposure \[[@CR41]--[@CR43]\]. Most of the trials included in our study supplemented prebiotics by adding oligosaccharide into breast milk or formula \[[@CR10], [@CR15], [@CR17]--[@CR19], [@CR21]--[@CR23]\], while other trials used distilled water as a medium \[[@CR11], [@CR12], [@CR24]\]. In our study, trials using breast milk or formula as a medium to supply prebiotics had significant pooled effects on reducing sepsis. This effect is in line with the ability of pAOS, which are designed to act as receptors-analogs, preventing pathogens from adhering to the epithelial surface of the digestive tract \[[@CR44]\]. The heterogeneity among the trials included was not significant, indicating that the effect of breast milk intake on lowering the morbidity rate of sepsis was consistent. Beyond nutritional components, breast milk contains some important bioactive substances such as microbes, oligosaccharides, cytokines, immunoglobulins, and proteins, which directly influence the development of infants and shape their intestinal microbiota colonization \[[@CR45]\]. These bioactive substances are considered not only protective but also stimulate the development and maturation of the immature immune system \[[@CR46]\]. This could explain why we observed better results in trials using a combination of breast milk or formula as a medium to supply prebiotics rather than trials that used distilled water.

Healthcare for preterm infants face many problems in feeding, because of the increased morbidity rate of NEC and feeding intolerance, full enteral feeding is often difficult. The pooled effects based on our meta-analysis showed a notable reduced time to enteral feeding with the administration of prebiotics to preterm infants. Prebiotic supplement increases the abundances of prebiotics, such as *bifidobacteria* and *lactobacillus*, and reduce the abundance of potential pathogenic bacteria in gut microbiota of preterm infants \[[@CR47], [@CR48]\]. The colonization of beneficial bacteria can improve stool frequency and consistency, which in turn promote the enteral feeding tolerance and shorten the time to achieve full enteral feeding in preterm infants \[[@CR26]\].

There were no significant differences on two items, including the morbidity rate of NEC and feeding intolerance. The morbidity of NEC could be explained by active medical intervention in the NICUs addressed infection risks such as proper fasting and parenteral nutrition \[[@CR3]\]. The effectiveness of early detection and prevention of NEC varied from rural hospitals with relative poor medical technology to teaching hospitals in cities \[[@CR2], [@CR9]\]. Most of the 18 trials were conducted in teaching hospitals, in which early diagnosis and prophylactic treatment can be made by experienced clinicians. The lack of effect of prebiotics on reducing the development of NEC could also be partially due to the fact that oligosaccharides employed in the trials (scGOS, lcFOS, and pAOS) have completely different structures compared to the oligosaccharides of human milk \[[@CR46]\], especially when they are applied to preterm infants who have a different microbiota system than full-term infants \[[@CR49]\]. In consideration of the immature gastrointestinal tract and immune system of preterm infants, prebiotic supplementation should be administered with caution \[[@CR9]\]. With regards to feeding intolerance, subgroup analysis suggests that prebiotics used in these trials were well tolerated by preterm infants. According to two studies \[[@CR14], [@CR16]\], the maximum supplementation dose of 1.5 g/kg/day appears to be effective and safe.

Limitation {#Sec17}
----------

The limitation of our study is that all the variables reflect the micro-ecological balance in intestinal flora indirectly. Some early trials measured the number of bacterial colonies by cultivation which is subject to error and is potentially heterogeneous. With the development of second-generation sequencing, further RCTs are required to clarify the stains and their proportion in stool using 16S RNA sequencing or metagenomic sequencing. Only in this way can we reveal the mechanism of prebiotics on intestinal flora and preterm infant's health directly.

Clinical implications {#Sec18}
---------------------

The results of our study showed that prebiotics could provide significant benefits for preterm infant, including reductions of the incidence of sepsis, mortality, and time to achieve full enteral feeding. Considering these outcomes, the prebiotics supplement in NICUs would be highly beneficial for preterm infants. Prebiotics administration did little in reducing NEC and sepsis in very preterm infants. A new approach in gut microbiota management of infants is the administration of synbiotics, by combining the effect of probiotics and prebiotics. The growth of added live beneficial bacteria (probiotics) may be stimulated by specific substrates (prebiotics), which could improve the survival rate of the probiotics and provide readily substrates for fermentation. As one of the non-human milk oligosaccharides, pAOS have been produced to mimic human milk oligosaccharides. The Th2-type immune response could be attenuated better by pAOS than neutral oligosaccharides (scGOS and lcFOS) alone \[[@CR50]\].

Overall, the results of our study showed that prebiotics administration is effective in reducing the prevalence rates of sepsis and death, shortens the time to achieve full enteral feeding and hospital stay, and increases the stool frequency. Prebiotics supplement is more effective on infants ≥28 weeks, especially when administered in accompany with breast milk plus formula, added pAOS. Prebiotics may provide a novel approach to reduce the high incidence of complications caused by sepsis and improve the health of preterm infants.
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